{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:01Z","timestamp":1786119661325,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/mph.0b013e3181e92af4","type":"journal-article","created":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T06:05:07Z","timestamp":1285913107000},"page":"e314-e316","source":"Crossref","is-referenced-by-count":1,"title":["Reduced Methotrexate Clearance and Renal Impairment in a Boy With Osteosarcoma and Earlier Undetected Autosomal Dominant Polycystic Kidney Disease (ADPKD)"],"prefix":"10.1097","volume":"32","author":[{"given":"Martin","family":"Alberer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hoefele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Hilberath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Pawlita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus R.","family":"Benz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210227","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2006121387","article-title":"Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease","volume":"18","author":"Rossetti","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R2-17-20210227","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1681\/ASN.V7102142","article-title":"Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2","volume":"7","author":"Torra","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R3-17-20210227","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat Genet"},{"key":"R4-17-20210227","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MNH.0b013e3283262ab0","article-title":"Advances in the pathogenesis and treatment of polycystic kidney disease","volume":"18","author":"Patel","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R5-17-20210227","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3904\/kjim.2009.24.3.165","article-title":"Autosomal dominant polycystic kidney disease: 2009 update for internists","volume":"24","author":"Bennett","year":"2009","journal-title":"Korean J Intern Med"},{"key":"R6-17-20210227","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2215\/CJN.00060108","article-title":"Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the crisp and halt-pkd studies","volume":"3","author":"Chapman","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-17-20210227","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"R8-17-20210227","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2369-8-13","article-title":"Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study","volume":"8","author":"Serra","year":"2007","journal-title":"BMC Nephrol"},{"key":"R9-17-20210227","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2106\/00004623-197052030-00001","article-title":"Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases","volume":"52","author":"Marcove","year":"1970","journal-title":"J Bone Joint Surg Am"},{"key":"R10-17-20210227","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/1120009X.1990.11738996","article-title":"The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively","volume":"2","author":"Bacci","year":"1990","journal-title":"J Chemother"},{"key":"R11-17-20210227","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.1998.16.7.2452","article-title":"Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol","volume":"16","author":"Meyers","year":"1998","journal-title":"J Clin Oncol"},{"key":"R12-17-20210227","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/1097-0142(19950301)75:5<1084::AID-CNCR2820750506>3.0.CO;2-F","article-title":"Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival","volume":"75","author":"Saeter","year":"1995","journal-title":"Cancer"},{"key":"R13-17-20210227","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/pbc.22136","article-title":"The role of interferons in the treatment of osteosarcoma","volume":"54","author":"Whelan","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R14-17-20210227","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00280-008-0757-z","article-title":"Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency","volume":"63","author":"Ekhart","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"R15-17-20210227","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/(SICI)1096-911X(199903)32:3<177::AID-MPO3>3.0.CO;2-H","article-title":"Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients","volume":"32","author":"Rossi","year":"1999","journal-title":"Med Pediatr Oncol"},{"key":"R16-17-20210227","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/02841868809090322","article-title":"Renal insufficiency in patients treated with high dose methotrexate","volume":"27","author":"Maiche","year":"1988","journal-title":"Acta Oncol"},{"key":"R17-17-20210227","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0140-6736(86)90786-5","article-title":"Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen","volume":"1","author":"Thyss","year":"1986","journal-title":"Lancet"},{"key":"R18-17-20210227","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/019131200750035058","article-title":"Microvascular perturbations in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate","volume":"24","author":"Fuskevag","year":"2000","journal-title":"Ultrastruct Pathol"},{"key":"R19-17-20210227","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/clinchem\/42.8.1322","article-title":"Concepts in use of high-dose methotrexate therapy","volume":"42","author":"Treon","year":"1996","journal-title":"Clin Chem"},{"key":"R20-17-20210227","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(99)00041-8","article-title":"Crystal-induced acute renal failure","volume":"106","author":"Perazella","year":"1999","journal-title":"Am J Med"},{"key":"R21-17-20210227","first-page":"1407","article-title":"A rapid and specific radioimmunoassay for methotrexate","volume":"35","author":"Raso","year":"1975","journal-title":"Cancer Res"},{"key":"R22-17-20210227","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/pbc.20471","article-title":"Methotrexate induces cell swelling and necrosis in renal tubular cells","volume":"46","author":"Gr\u00f6nroos","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"R23-17-20210227","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0272-6386(12)70338-4","article-title":"An ultrasound renal cyst prevalence survey: specificity data for inherited renal cystic diseases","volume":"22","author":"Ravine","year":"1993","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0b013e3181e92af4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:41:38Z","timestamp":1786041698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-201011000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e3181e92af4","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}